Literature DB >> 18827038

Signaling pathways involved in the antiproliferative effect of molecular iodine in normal and tumoral breast cells: evidence that 6-iodolactone mediates apoptotic effects.

O Arroyo-Helguera1, E Rojas, G Delgado, C Aceves.   

Abstract

Previous reports have documented the antiproliferative properties of I(2) and the arachidonic acid (AA) derivative 6-iodolactone (6-IL) in both thyroid and mammary glands. In this study, we characterized the cellular pathways activated by these molecules and their effects on cell cycle arrest and apoptosis in normal (MCF-12F) and cancerous (MCF-7) breast cells. Low-to-moderate concentrations of I(2) (10-20 microM) cause G1 and G2/M phase arrest in MCF-12F and caspase-dependent apoptosis in MCF-7 cells. In normal cells, only high doses of I(2) (40 microM) induced apoptosis, and this effect was mediated by poly (ADP-ribose) polymerase-1 (PARP1) and the apoptosis-induced factor, suggesting an oxidative influence of iodine at high concentrations. Our data indicate that both I(2) and 6-IL trigger the same intracellular pathways and suggest that the antineoplasic effect of I(2) in mammary cancer involves the intracellular formation of 6-IL. Mammary cancer cells are known to contain high concentrations of AA, which might explain why I(2) exerts apoptotic effects at lower concentrations only in tumoral cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18827038     DOI: 10.1677/ERC-08-0125

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  12 in total

1.  Antiproliferative/cytotoxic effects of molecular iodine, povidone-iodine and Lugol's solution in different human carcinoma cell lines.

Authors:  Harald Rösner; Wolfgang Möller; Sabine Groebner; Pompilio Torremante
Journal:  Oncol Lett       Date:  2016-07-05       Impact factor: 2.967

Review 2.  The extrathyronine actions of iodine as antioxidant, apoptotic, and differentiation factor in various tissues.

Authors:  Carmen Aceves; Brenda Anguiano; Guadalupe Delgado
Journal:  Thyroid       Date:  2013-08       Impact factor: 6.568

3.  Iodine uptake and prostate cancer in the TRAMP mouse model.

Authors:  Paloma Olvera-Caltzontzin; Guadalupe Delgado; Carmen Aceves; Brenda Anguiano
Journal:  Mol Med       Date:  2013-11-08       Impact factor: 6.354

4.  Potassium Iodide Nanoparticles Enhance Radiotherapy against Breast Cancer by Exploiting the Sodium-Iodide Symporter.

Authors:  Benjamin L Cline; Wen Jiang; Chaebin Lee; Zhengwei Cao; Xueyuan Yang; Shuyue Zhan; Harrison Chong; Tao Zhang; Zhaoguo Han; Xuedan Wu; Li Yao; Hui Wang; Weizhong Zhang; Zibo Li; Jin Xie
Journal:  ACS Nano       Date:  2021-10-25       Impact factor: 18.027

5.  Activation of peroxisome proliferator-activated receptor gamma is crucial for antitumoral effects of 6-iodolactone.

Authors:  Mario Nava-Villalba; Rosa E Nuñez-Anita; Alexander Bontempo; Carmen Aceves
Journal:  Mol Cancer       Date:  2015-09-17       Impact factor: 27.401

6.  Molecular iodine/doxorubicin neoadjuvant treatment impair invasive capacity and attenuate side effect in canine mammary cancer.

Authors:  Xóchitl Zambrano-Estrada; Brianda Landaverde-Quiroz; Andrés A Dueñas-Bocanegra; Marco A De Paz-Campos; Gerardo Hernández-Alberto; Benjamín Solorio-Perusquia; Manuel Trejo-Mandujano; Laura Pérez-Guerrero; Evangelina Delgado-González; Brenda Anguiano; Carmen Aceves
Journal:  BMC Vet Res       Date:  2018-03-12       Impact factor: 2.741

7.  Biochemical properties of thyroid peroxidase (TPO) expressed in human breast and mammary-derived cell lines.

Authors:  Marlena Godlewska; Wanda Krasuska; Barbara Czarnocka
Journal:  PLoS One       Date:  2018-03-07       Impact factor: 3.240

8.  Antineoplastic effect of iodine in mammary cancer: participation of 6-iodolactone (6-IL) and peroxisome proliferator-activated receptors (PPAR).

Authors:  Carmen Aceves; Pablo García-Solís; Omar Arroyo-Helguera; Laura Vega-Riveroll; Guadalupe Delgado; Brenda Anguiano
Journal:  Mol Cancer       Date:  2009-06-06       Impact factor: 27.401

9.  Iodine and doxorubicin, a good combination for mammary cancer treatment: antineoplastic adjuvancy, chemoresistance inhibition, and cardioprotection.

Authors:  Yunuen Alfaro; Guadalupe Delgado; Alfonso Cárabez; Brenda Anguiano; Carmen Aceves
Journal:  Mol Cancer       Date:  2013-05-24       Impact factor: 27.401

10.  Molecular iodine inhibits the expression of stemness markers on cancer stem-like cells of established cell lines derived from cervical cancer.

Authors:  Gabriele Davide Bigoni-Ordóñez; Elizabeth Ortiz-Sánchez; Pedro Rosendo-Chalma; Heriberto A Valencia-González; Carmen Aceves; Alejandro García-Carrancá
Journal:  BMC Cancer       Date:  2018-09-26       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.